Federal Register notice: FDA posts four recent information collections that have been approved by OMB.
FDA publishes a guidance to help companies be ready to quickly and effectively remove recalled products from the market.
The Los Angeles Times raises concerns about FDAs use of accelerated approval pathways for many new drugs.
The Sedgwick recall index for 2021 shows that both medical devices and drugs had fewer recalls and the recalls involved more units.
The Personalized Medicine Coalition says FDA is accelerating its involvement in personalized medicine.
Federal Register notice: FDA seeks comments on an information collection extension entitled Emergency Use Authorization of Medical Products.
FDA tells Karyopharm clinical trial results are unlikely to support approval of its selinexor as maintenance therapy for endometrial cancer patients f...
Federal Register notice: FDA posts a final guidance entitled Inclusion of Older Adults in Cancer Clinical Trials.